logo
Share SHARE
FONT-SIZE Plus   Neg

Genentech Says SUMMACTA Study Meets Primary Endpoint - Quick Facts

Genentech, a member of the Roche Group (RHHBY.PK), announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy (non-inferiority) of the subcutaneous formulation of ACTEMRA (tocilizumab) 162mg weekly compared to 8 mg/kg ACTEMRA intravenous formulation every four weeks.

A similar proportion of rheumatoid arthritis patients in each group achieved an ACR20 response at Week 24, a measure indicating improvement in the number of tender and swollen joints, pain scale, patients' and physicians' assessment of improvement and certain laboratory markers.

Hal Barron, chief medical officer and head, Global Product Development, stated, "We are very pleased with these data showing that subcutaneous administration of ACTEMRA provides clinically meaningful and comparable results to the IV infusion. This may provide patients and their doctors with an important additional treatment option."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Justice Department has initiated a probe to find out if airlines are colluding to limit seating capacity in order to benefit from higher airfares. Saudi Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud has pledged to give away his entire wealth amounting to $32 billion for charity. He said the fund will be utilized for cultural understanding, develop communities, empower women, enable youth, provide vital disaster relief and create a more tolerant and accepting world. Toyota accepted the resignation of its Chief Communications Officer Julie Hamp, following her arrest in Japan for allegedly mailing banned painkillers to her address in Japan from U.S.
comments powered by Disqus
Follow RTT